

Test Performed: IMMUNODEFICIENCY

Report Date **Feb 6, 2023**
Status **FINAL**

Patient
Patient Name
Date of Birth Dec 29, 1946
Sex Female

Symptoms Not Applicable
Indication Hereditary Disorder

Client
Client Molecular
Clinical Laboratory
Physician Pierce

Specimen
Accession ID 23-52
Specimen Saliva
Collection Dec 12, 2022
Accession Feb 4, 2023

Result: Positive

1
Pathogenic

Variant Summary

Gene / Variant	Genotype	Assessment	Mode of Inheritance	Phenotype
CCDC107 c.-432T>C g.35657948T>C	Heterozygous	Pathogenic	recessive	Cartilage-hair hypoplasia

Individual Variant Interpretations

Gene **CCDC107**
Exon 0
Amino Acid
Nucleotide NM_174923.3:
g.35657948T>C
c.-432T>C
Assessment **Pathogenic**
Genotype Heterozygous

Interpretation

Cartilage-hair hypoplasia is a disorder of bone growth characterized by short stature (dwarfism) with other skeletal abnormalities; fine, sparse hair ([hypotrichosis](#)); and abnormal immune system function (immune deficiency) that can lead to recurrent infections.

People with cartilage-hair hypoplasia have unusually short limbs and short stature from birth. They typically have malformations in the cartilage near the ends of the long bones in the arms and legs (metaphyseal chondrodysplasia), which then affects development of the bone itself. Most people with cartilage-hair hypoplasia are unusually flexible in some joints, but they may have difficulty extending their elbows fully.

Affected individuals have hair that is lighter in color than that of other family members because the core of each hair, which contains some of the pigment that contributes the hair's color, is missing. The missing core also makes each strand of hair thinner, causing the hair to have a sparse appearance overall. Unusually light-colored skin (hypopigmentation), malformed nails, and dental abnormalities may also be seen in this disorder.

The extent of the immune deficiency in cartilage-hair hypoplasia varies from mild to severe. Affected individuals with the most severe immune problems are considered to have severe combined immunodeficiency (SCID). People with SCID lack virtually all immune protection from

bacteria, viruses, and fungi and are prone to repeated and persistent infections that can be very serious or life-threatening. These infections are often caused by "opportunistic" organisms that ordinarily do not cause illness in people with a normal immune system. Most people with cartilage-hair hypoplasia, even those who have milder immune deficiency, experience infections of the [respiratory system](#), ears, and [sinuses](#). In particular, the chicken pox virus (varicella) often causes dangerous infections in people with this disorder. Autoimmune disorders, which occur when the immune system malfunctions and attacks the body's tissues and organs, occur in some people with cartilage-hair hypoplasia. Affected individuals are also at an increased risk of developing cancer, particularly certain skin cancers ([basal cell carcinomas](#)), cancer of blood-forming cells ([leukemia](#)), and cancer of immune system cells ([lymphoma](#)).

Some people with cartilage-hair hypoplasia experience gastrointestinal problems. These problems may include an inability to properly absorb nutrients or intolerance of a protein called gluten found in wheat and other grains ([celiac disease](#)). Affected individuals may have [Hirschsprung disease](#), an intestinal disorder that causes severe constipation, intestinal blockage, and enlargement of the [colon](#). Narrowing of the anus (anal stenosis) or blockage of the esophagus ([esophageal atresia](#)) may also occur.

Genes Tested

ACD, ACP5, ACTA2, ACTB, ACTC1, ACVRL1, ADA, ADA2, ADAM17, ADAMTS13, ADAR, AICDA, AIRE, AK2, AP1S3, AP3B1, AP3D1, APC, APOB, APOL1, ARPC1B, ATM, ATP6AP1, ATP7B, B2M, BACH2, BCL10, BCL11B, BLM, BLNK, BLOC1S3, BLOC1S6, BMPRIA, BRCA1, BRCA2, BRIP1, BTD, BTK, C1QA, C1QB, C1QC, C1R, C1S, C2, C3, C4BPA, C5, C6, C7, C8A, C8B, C8G, C9, CACNA1S, CARD11, CARD14, CARD9, CARMIL2, CASP10, CASP8, CASQ2, CAVIN1, CCBET, CCDC103, CCDC39, CCDC40, CCDC65, CCNO, CD19, CD247, CD27, CD3D, CD3E, CD3G, CD40, CD40LG, CD46, CD55, CD59, CD70, CD79A, CD79B, CD81, CD8A, CDCA7, CEBPE, CENPF, CFAP298, CFB, CFD, CFH, CFHR1, CFHR2, CFHR3, CFHR4, CFHR5, CFI, CFP, CFTR, CHD7, CIITA, CLCN7, CLEC7A, CLPB, COG6, COL3A1, COLEC1, COPA, CORO1A, CR2, CREBBP, CSF2RA, CSF2RB, CSF3R, CTC1, CTLA4, CTPS1, CTSC, CXCR4, CYBA, CYBB, DCLRE1B, DCLRE1C, DDX58, DGKE, DHFR, DKC1, DNAAF1, DNAAF2, DNAAF3, DNAAF4, DNAAF5, DNAH1, DNAH11, DNAH5, DNAI1, DNAI2, DNAJC21, DNAL1, DNASE1L3, DNASE2, DNMT3B, DOCK2, DOCK8, DRC1, DSC2, DSG2, DSP, DTNBP1, ELANE, ENG, EPG5, ERCC2, ERCC3, ERCC4, ERCC6L2, ETV6, EXTL3, F11, F13A1, F13B, F5, F7, F8, F9, FAAP24, FADD, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FAS, FASLG, FAT4, FBN1, FCGR3A, FCN3, FERMT3, FGA, FGB, FLNC, FOXN1, FOXP3, FPR1, G6PC3, G6PD, GAA, GAS8, GATA1, GATA2, GFII1, GINS1, GLA, GPIBA, GPIBB, GP9, GTF2H5, HAX1, HELLS, HFE, HNF1A, HPS1, HPS3, HPS4, HPSS, HPS6, HYDIN, HYU1, ICOS, IFIH1, IFNAR2, IFNGR1, IFNGR2, IGLL1, IKBKB, IKZF1, IL10, IL10RA, IL10RB, IL12RB1, IL17F, IL17RA, IL17RC, IL1RN, IL2, IL21, IL21R, IL2RA, IL2RG, IL36RN, IL7R, INO80, INSR, INVS, IRAK1, IRAK4, IRF2BP2, IRF3, IRF7, IRF8, ISG15, ITCH, ITGAM, ITGB2, ITK, JAGN1, JAK1, JAK2, JAK3, KCNH2, KCNQ1, KDM6A, KMT2D, KRAS, LAMTOR2, LAT, LCK, LDLR, LIG1, LIG4, LMNA, LPIN2, LRBA, LRRC8A, LYST, MAGT1, MALT1, MAN2B1, MANBA, MAP3K14, MASP1, MASP2, MAX, MBL2, MC2R, MCM4, MEFV, MEN1, MLH1, MLPH, MOGS, MPL, MPO, MRE11, MS4A1, MSH2, MSH6, MSN, MTHFD1, MUTYH, MVK, MYBPC3, MYD88, MYH11, MYH7, MYH9, MYL2, MYL3, MYO5A, MYSM1, NBAS, NBN, NCF1, NCF2, NCF4, NCSTN, NF2, NFAT5, NFKB1, NFKB2, NFKBIA, NHEJ1, NHP2, NKX2-5, NLRC4, NLRP1, NLRP12, NLRP3, NME8, NOD2, NOPI0, NRAS, NSMCE3, OFD1, ORAI1, OSTM1, OTC, OTULIN, PALB2, PARN, PCCA, PCCB, PCSK9, PEPD, PGM3, PI4KA, PIGA, PIK3CD, PIK3R1, PKP2, PLCG2, PLEKHM1, PLG, PMM2, PMS2, PNP, POLA1, POLE, POLE2, PRF1, PRKAG2, PRKCD, PRKDC, PROC, PROS1, PSENEN, PSMB8, PSTPIP1, PTEN, PTPRC, RAB27A, RAC2, RAD50, RAD51C, RAG1, RAG2, RANBP2, RASGRP1, RBL1, RBCK1, RBM8A, RECQL4, RELB, RET, RFX5, RFXANK, RFXAP, RHOH, RMRP, RNASEH2A, RNASEH2B, RNASEH2C, RNF168, RNF31, RORC, RPE65, RPGR, RPL11, RPL15, RPL26, RPL35A, RPL36, RPL5, RPS10, RPS15, RPS15A, RPS17, RPS19, RPS24, RPS26, RPS27A, RPS28, RPS29, RPS7, RPSA, RSPH1, RSPH3, RSPH4A, RSPH9, RTEL1, RUNX1, RYR1, RYR2, SAMD9, SAMD9L, SAMHD1, SBDS, SCN5A, SDHAF2, SDHB, SDHC, SDHD, SEMA3E,

SERPING1, SH2D1A, SH3BP2, SKIV2L, SLC29A3, SLC35A1, SLC35C1, SLC37A4, SLC39A4, SLC46A1, SLC7A7, SLX4, SMAD3, SMAD4, SMARCA1, SMARCD2, SNX10, SPI10, SPAG1, SPINK5, SRP54, SRP72, STAT1, STAT2, STAT3, STAT5B, STIM1, STK11, STK4, STN1, STX11, STXBP2, TAP1, TAP2, TAPBP, TBK1, TBX1, TCF3, TCIRG1, TCN2, TERC, TERT, TFRC, TGFBR1, TGFBR2, THBD, TICAM1, TINF2, TIRAP, TLR3, TMC6, TMC8, TMEM127, TMEM43, TNFAIP3, TNFRSF11A, TNFRSF13B, TNFRSF13C, TNFRSF14, TNFRSF4, TNFSF11, TNFSF12, TNNT3, TNNT2, TP53, TPM1, TPP1, TPP2, TRADD, TRAF3, TRAF3IP2, TRDN, TREX1, TRNT1, TSC1, TSC2, TTC37, TTC7A, TTN, TYK2, UNC119, UNC13D, UNC93B1, UNG, USB1, USPI8, VHL, VPS13B, VPS45, WAS, WDR1, WIPF1, WRAP53, WT1, XIAP, XK, ZAP70, ZBTB24, ZMYND10

Methods and Limitations

DNA is extracted from patient specimens using a solid-phase technology. Individual samples are barcoded and enriched for exonic or coding portions of the genome using the IDT x-Gen Exome Research Panel v2. Sequencing is performed using Illumina SBS technology on the NovaSeq 6000.

Sequencing data from the NovaSeq 6000 is uploaded to the BaseSpace cloud and demultiplexed using the FASTQ generation workflow and bcl2fastq2 software. The resulting FASTQ files are processed using the DRAGEN germline 3.6.3 app with predefined targets via two custom biosample workflows (Genzeva_Dragen_v0_1 and Genzeva_Dragen_v0_2).

Genzeva uses the following software packages and scripts to perform analysis:

Illumina Software Packages

DRAGEN germline v3.6.3
FASTQ generation v1.0.0
bcl2fastq2 v2.2

Genzeva Server Software

Python v3.6.9
bcftools v1.9
htslib v1.9
bedtools 2.25.0
tabix v1.9
bgzip v1.9
BaseSpace CLI v1.2.1
Ubuntu v18.04 LTS

Python packages

sample-sheet v0.12.0
certifi v2020.6.20
chardet v3.0.4
click v7.1.2
idna v2.10
requests 2.24.0
tabulate v0.8.7
terminaltables v3.1.0
urllib3 v1.25.11

Custom Scripts

parse.gvcf.sh
parse.gvcf.py

parse_split.gvcf.py
bssh_interface.sh
bssh_interface_wrapper.sh
parse_json.py

Automated passing of DRAGEN analysis output from BaseSpace to Genzeva Laboratory Information System utilizes BASH script bssh_interface.sh and underlying BaseSpace command line interface (CLI).

Specimens must pass the following QC criteria before variant interpretation and analysis.

Uniformity of coverage (Min) 97.015%
Covered Bases >20X (Min) 95.966%
Total Reads (Min) 49143135
Average Alignment (Min) 64.796%
Duplicate Reads (Max) 23.381%

Relevant panels for analysis are created virtually by analyzing the genes described above. Panel variant interpretation is performed to the ACMG Guidelines (PMID: 25741868), with relevant pathogenic and likely pathogenic variants published on the final patient report.

Performance metrics as determined by our validations are listed below:

Entire Exome Region
Accuracy- 99.999%
Sensitivity- 99.246%
Specificity- 100%
Positive Predictive Value- 99.927%
Negative Predictive Value- 99.999%

Limitations

This test aims to detect all clinically relevant variants within the coding regions of the genes listed using the methodology above. Pathogenic and Likely Pathogenic variants should be confirmed by orthogonal technology. Please contact client services for more information, or to order as a separate test. Intronic (within 20bp of coding region), homopolymer regions with single base repeats > 5bp, dinucleotide repeats > 10bp, and trinucleotide repeats > 15 bp and larger expansions cannot be captured by the standard NGS target enrichment protocols and/or sequenced accurately. At this time the assay does not detect large deletions or duplications. This test is not designed to detect complex gene rearrangements or genomic aneuploidy events. This analysis also cannot detect pathogenic variants within regions which were not analyzed (e.g. other genes not tested, introns, promoter and enhancer regions, long repeat regions, or mitochondrial sequences). This assay is not designed to detect mosaicism. Patients that are hemizygous for an allele are reported out as homozygous due to current pipeline constraints, this is most common on the X-chromosome for male patients.

Genzeva only interprets and reports findings within the genes that are included within the panel ordered. It is important to understand that there may be variants in these genes undetectable using current technology. Additionally, there may be genes associated with the patient's phenotype that are not part of the panel sequenced.

Regulatory Disclaimer

This test was developed and its performance characteristics determined Genzeva (CLIA# 21D2119113) It has not been cleared or approved by the US Food and Drug Administration. The FDA does not require this test to go through premarket FDA review. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing.

QIAGEN Clinical Insight (QCI™) is a variant analysis, interpretation and decision support tool for research and clinical labs analyzing human genetics data and is not intended to be used for diagnostic purposes. QCI Interpret software includes the following underlying databases, data reference sets and tools; QIAGEN Clinical Insight-Interpret (9.0.0.20220826), Ingenuity Knowledge Base (H-release), CADD (v1.6), NCBI Gene (2022-02-22), Allele Frequency Community (2019-09-25), EVS (ESP6500SI-V2), Refseq Gene Model (2022-02-22), JASPAR (2013-11), Ingenuity Knowledge Base Snapshot Timestamp (2022-11-12 13:22:36.407), Vista Enhancer hg18 (2012-07), Vista Enhancer hg19 (2012-07), Clinical Trials (H-release), MITOMAP: A Human Mitochondrial Genome Database. <http://www.mitomap.org>, 2019 (2020-06-19), PolyPhen-2 (v2.2.2 (HumVar)), 1000 Genome Frequency (phase3v5b), ExAC (0.3.1), iva (Jul 13 22:57), TargetScan (7.2), phyloP hg18 (NCBI36 (hg18) 2009-11, GRCh37 (hg19) 2014-02, GRCh38 2015-05), phyloP hg19 (NCBI36 (hg18) 2009-11, GRCh37 (hg19) 2014-02, GRCh38 2015-05), GENCODE (Release 37), CentoMD (5.3), dbVar (2021_04), OMIM (April 13, 2022), gnomAD (GRCh37 (hg19) 2.1.1, GRCh38 (hg38) 3.1.2), BSIFT (2016-02-23), TCGA (2013-09-05), Clinvar (2022-04-14), DGV (2016-05-15), COSMIC (v95), HGMD (2022.3), OncoTree (oncotree_2019_03_01), dbSNP (NCBI36 (hg18) 151, GRCh37 (hg19) 154, GRCh38 154), SIFT4G (2016-02-23)

Reviewed and approved by:



Dr. William G Kearns

Approved on: Feb 6, 2023

Selected Citations

1. Abolhassani H, Aghamohammadi A, Hammarström L (2016) Monogenic mutations associated with IgA deficiency. *Expert Rev Clin Immunol*. 2016 Dec;12(12):1321-1335. Epub 2016 Jun 21 ([PMID: 27266541](#))
2. Abul-Å A, Boada M, Rodríguez-Santiago B, Coroleu B, Veiga A, Armengol L, Barri PN, Páez-Jurado LA, Estivill X (2016) NGS-Based Assay for the Identification of Individuals Carrying Recessive Genetic Mutations in Reproductive Medicine. *Hum Mutat*. 2016 Jun;37(6):516-23. Epub 2016 Apr 15 ([PMID: 26990548](#))
3. Alabdullatif MA, Al Dhaibani MA, Khassawneh MY, El-Hattab AW (2016) Chromosomal microarray in a highly consanguineous population: diagnostic yield, utility of regions of homozygosity, and novel mutations. *Clin Genet*. 2017 Apr;91(4):616-622. Epub 2016 Oct 11 ([PMID: 27717089](#))
4. Biggs CM, Kostjukovits S, Dobbs K, Laakso S, Klemetti P, Valta H, Taskinen M, Mäkitie O, Notarangelo LD (2017) Diverse Autoantibody Reactivity in Cartilage-Hair Hypoplasia. *J Clin Immunol*. 2017 Aug;37(6):508-510. Epub 2017 Jun 19 ([PMID: 28631025](#))
5. Bonafé L, Schmitt K, Eich G, Giedion A, Superti-Furga A (2002) RMRP gene sequence analysis confirms a cartilage-hair hypoplasia variant with only skeletal manifestations and reveals a high density of single-nucleotide polymorphisms. *Clin Genet*. 2002 Feb;61(2):146-51 ([PMID: 11940090](#))
6. Bonafé L, Dermitzakis ET, Unger S, Greenberg CR, Campos-Xavier BA, Zankl A, Ucla C, Antonarakis SE, Superti-Furga A, Raymond A (2005) Evolutionary comparison provides evidence for pathogenicity of RMRP mutations. *PLoS Genet*. 2005 Oct;1(4):e47 ([PMID: 16244706](#))
7. Bordon V, Gennery AR, Slatter MA, Vandecruys E, Laureys G, Veys P, Qasim W, Friedrich W, Wulfraat NM, Scherer F, Cant AJ, Fischer A, Cavazzana-Calvo M, Bredius RG, Notarangelo LD, Mazzolari E, Neven B, GÃ¼ngör T, Inborn Error Working Party of the European Bone Marrow Transplantation (EBMT) group (2010) Clinical and immunologic outcome of patients with cartilage hair hypoplasia after hematopoietic stem cell transplantation. *Blood*. 2010 Jul 08;116(1):27-35. Epub 2010 Apr 7 ([PMID: 20375313](#))
8. Cossu F (2010) Genetics of SCID. *Ital J Pediatr*. 2010 Nov 15;36:76 ([PMID: 21078154](#))
9. Crahes M, Saugier-Verber P, Patrier S, Aziz M, Pirot N, Brasseur-Daudruy M, Layet V, FrÃ©bourg T, LaquerriÃ¨re A (2013) Foetal presentation of cartilage hair hypoplasia with extensive granulomatous inflammation. *Eur J Med Genet*. 2013 Jul;56(7):365-70. Epub 2013 May 2 ([PMID: 23643676](#))

10. Crowgey EL, Washburn MC, Kolb EA, Puffenberger EG (2019) Development of a Novel Next-Generation Sequencing Assay for Carrier Screening in Old Order Amish and Mennonite Populations of Pennsylvania. *J Mol Diagn.* 2019 Jul;21(4):687-694. Epub 2019 Apr 25 ([PMID: 31028937](#))
11. GiÅ1/4ewska M, Durda K, Winter T, Ostrowska I, OÅtarzewski M, Klein J, Blankenstein O, Romanowska H, KrzywiÅska-Zdeb E, Patalan MF, Bartkowiak E, Szczerbe N, Seiberling S, Birkenfeld B, Nauck M, von Bernuth H, Meisel C, Bernatowska EA, Walczak M, Pac M (2020) Newborn Screening for SCID and Other Severe Primary Immunodeficiency in the Polish-German Transborder Area: Experience From the First 14 Months of Collaboration. *Front Immunol.* 2020;11:1948. Epub 2020 Oct 16 ([PMID: 33178177](#))
12. Cuggenheim R, Somech R, Grunebaum E, Atkinson A, Roifman CM (2006) Bone marrow transplantation for cartilage-hair-hypoplasia. *Bone Marrow Transplant.* 2006 Dec;38(11):751-6. Epub 2006 Oct 16 ([PMID: 17041608](#))
13. Hall CM, Liu B, Haworth A, Reed L, Pryce J, Mansour S (2021) Early prenatal presentation of the cartilage-hair hypoplasia / anauxetic dysplasia spectrum of disorders mimicking recurrent thanatophoric dysplasia. *Eur J Med Genet.* 2021 Mar;64(3):104162. Epub 2021 Feb 7 ([PMID: 33567347](#))
14. Hermanns P, Bertuch AA, Bertin TK, Dawson B, Schmitt ME, Shaw C, Zabel B, Lee B (2005) Consequences of mutations in the non-coding RMRP RNA in cartilage-hair hypoplasia. *Hum Mol Genet.* 2005 Dec 01;14(23):3723-40. Epub 2005 Oct 27 ([PMID: 16254002](#))
15. Hermanns P, Tran A, Munivez E, Carter S, Zabel B, Lee B, Leroy JG (2006) RMRP mutations in cartilage-hair hypoplasia. *Am J Med Genet A.* 2006 Oct 01;140(19):2121-30 ([PMID: 16838329](#))
16. Hirose Y, Nakashima E, Ohashi H, Mochizuki H, Bando Y, Ogata T, Adachi M, Toba E, Nishimura G, Ikegawa S (2006) Identification of novel RMRP mutations and specific founder haplotypes in Japanese patients with cartilage-hair hypoplasia. *J Hum Genet.* 2006;51(8):706-710. Epub 2006 Jul 11 ([PMID: 16832578](#))
17. Holopainen E, Vakkilainen S, MÅxkitie O (2018) Gynecologic assessment of 19 adult females with cartilage-hair hypoplasia - high rate of HPV positivity. *Orphanet J Rare Dis.* 2018 Nov 16;13(1):207 ([PMID: 30445974](#))
18. Hou YC, Yu HC, Martin R, Cirulli ET, Schenker-Ahmed NM, Hicks M, Cohen IV, JÅ1nsson TJ, Heister R, Napier L, Swisher CL, Dominguez S, Tang H, Li W, Perkins BA, Barea J, Rybak C, Smith E, Duchicela K, Doney M, Brar P, Hernandez N, Kirkness EF, Kahn AM, Venter JC, Karow DS, Caskey CT (2020) Precision medicine integrating whole-genome sequencing, comprehensive metabolomics, and advanced imaging. *Proc Natl Acad Sci U S A.* 2020 Feb 11; 117(6):3053-3062. Epub 2020 Jan 24 ([PMID: 31980526](#))
19. Ip W, Gaspar HB, Kleta R, Chanudet E, Bacchelli C, Pitts A, Nademi Z, Davies EG, Slatter MA, Amrolia P, Rao K, Veys P, Gennery AR, Qasim W (2015) Variable phenotype of severe immunodeficiencies associated with RMRP gene mutations. *J Clin Immunol.* 2015 Feb;35(2):147-57. Epub 2015 Feb 8 ([PMID: 25663137](#))
20. Iqbal M, Muhammad N, Ali SA, Kostjukovits S, MÅkitie O, Naz S (2017) The Finnish founder mutation c.70 A>G in RMRP causes cartilage-hair hypoplasia in a Pakistani family. *Clin Dysmorphol.* 2017 Apr;26(2):121-123 ([PMID: 27740950](#))
21. Kainulainen L, Lassila O, Ruuskanen O (2014) Cartilage-hair hypoplasia: follow-up of immunodeficiency in two patients. *J Clin Immunol.* 2014 Feb;34(2):256-9. Epub 2014 Jan 9 ([PMID: 24402619](#))
22. Kavadas FD, Giliani S, Gu Y, Mazzolari E, Bates A, Pegoiani E, Roifman CM, Notarangelo LD (2008) Variability of clinical and laboratory features among patients with ribonuclease mitochondrial RNA processing endoribonuclease gene mutations. *J Allergy Clin Immunol.* 2008 Dec;122(6):1178-84. Epub 2008 Sep 19 ([PMID: 18804272](#))
23. Khan S, Pereira J, Darbyshire PJ, Holding S, DorÅ© PC, Sewell WA, Huissoon A (2010) Do ribosomopathies explain some cases of common variable immunodeficiency? *Clin Exp Immunol.* 2011 Jan;163(1):96-103. Epub 2010 Nov 9 ([PMID: 21062271](#))
24. Klemetti P, Valta H, Kostjukovits S, Taskinen M, Toiviainen-Salo S, MÅxkitie O (2017) Cartilage-hair hypoplasia with normal height in childhood-4 patients with a unique genotype. *Clin Genet.* 2017 Aug;92(2):204-207. Epub 2017 Mar 19 ([PMID: 28094436](#))
25. Kostjukovits S, Degerman S, Pekkinen M, Klemetti P, Landfors M, Roos G, Taskinen M, MÅxkitie O (2016) Decreased telomere length in children with cartilage-hair hypoplasia. *J Med Genet.* 2017 May;54(5):365-370. Epub 2016 Dec 16 ([PMID: 27986801](#))

26. Kuijpers TW, Ridanpää M, Peters M, de Boer I, Vossen JM, Pals ST, Kaitila I, Hennekam RC (2003) Short-limbed dwarfism with bowing, combined immune deficiency, and late onset aplastic anaemia caused by novel mutations in the RMPR gene. *J Med Genet.* 2003 Oct;40(10):761-6 ([PMID: 14569125](#))
27. Lam AC, Chan DH, Tong TM, Tang MH, Lo SY, Lo IF, Lam ST (2006) Metaphyseal chondrodysplasia McKusick type in a Chinese fetus, caused by novel compound heterozygosity 64T> A and 79G >T in RMRP gene. *Prenat Diagn.* 2006 Nov;26(11):1018-20 ([PMID: 16941720](#))
28. Lugli L, Ciancia S, Bertucci E, Lucaccioni L, Calabrese O, Madeo S, Berardi A, Iughetti L (2021) Homozygous n.64C>T mutation in mitochondrial RNA-processing endoribonuclease gene causes cartilage hair hypoplasia syndrome in two siblings. *Eur J Med Genet.* 2021 Feb;64(2):104136. Epub 2021 Jan 12 ([PMID: 33444820](#))
29. Martin AN, Li Y (2007) RNase MRP RNA and human genetic diseases. *Cell Res.* 2007 Mar;17(3):219-26 ([PMID: 17189938](#))
30. Mattijssen S, Hinson ER, Onnekink C, Hermanns P, Zabel B, Cresswell P, Pruijn GJ (2010) Viperin mRNA is a novel target for the human RNase MRP/RNase P endoribonuclease. *Cell Mol Life Sci.* 2011 Jul;68(14):2469-80. Epub 2010 Oct 30 ([PMID: 21053045](#))
31. Mattijssen S, Welting TJ, Pruijn GJ (2010) RNase MRP and disease. *Wiley Interdiscip Rev RNA.* 2010 Jul-Aug;1(1):102-16. Epub 2010 May 6 ([PMID: 21956908](#))
32. Muñoz-Robles J, Allende LM, Clemente J, Calleja S, Varela P, Gonzalez L, de Pablos P, Paz E, Morales P (2006) A novel RMRP mutation in a Spanish patient with cartilage-hair hypoplasia. *Immunobiology.* 2006;211(9):753-7. Epub 2006 Jun 23 ([PMID: 17015150](#))
33. Nakashima E, Mabuchi A, Kashimada K, Onishi T, Zhang J, Ohashi H, Nishimura G, Ikegawa S (2003) RMRP mutations in Japanese patients with cartilage-hair hypoplasia. *Am J Med Genet A.* 2003 Dec 15;123A(3):253-6 ([PMID: 14608646](#))
34. Nakashima E, Tran JR, Welting TJ, Pruijn GJ, Hirose Y, Nishimura G, Ohashi H, Schurman SH, Cheng J, Candotti F, Nagaraja R, Ikegawa S, Schlessinger D (2007) Cartilage hair hypoplasia mutations that lead to RMRP promoter inefficiency or RNA transcript instability. *Am J Med Genet A.* 2007 Nov 15;143A(22):2675-81 ([PMID: 17937437](#))
35. Narayanan DL, Shukla A, Siddesh AR, Stephen J, Srivastava P, Mandal K, Phadke SR (2016) Cartilage Hair Hypoplasia: Two Unrelated Cases with g.70 A→G Mutation in RMRP Gene. *Indian J Pediatr.* 2016 Sep;83(9):1003-5. Epub 2016 Feb 1 ([PMID: 26830278](#))
36. Puffenberger EG (2003) Genetic heritage of the Old Order Mennonites of southeastern Pennsylvania. *Am J Med Genet C Semin Med Genet.* 2003 Aug 15;121C(1):18-31 ([PMID: 12888983](#))
37. Ridanpää M, Jain P, McKusick VA, Francomano CA, Kaitila I (2003) The major mutation in the RMRP gene causing CHH among the Amish is the same as that found in most Finnish cases. *Am J Med Genet C Semin Med Genet.* 2003 Aug 15;121C(1):81-3 ([PMID: 12888988](#))
38. Ridanpää M, Sistonen P, Rockas S, Rimoin DL, Mäkitie O, Kaitila I (2002) Worldwide mutation spectrum in cartilage-hair hypoplasia: ancient founder origin of the major 70A→G mutation of the untranslated RMRP. *Eur J Hum Genet.* 2002 Jul;10(7):439-47 ([PMID: 12107819](#))
39. Ridanpää M, Ward LM, Rockas S, Särkioja M, Mäkelä H, Susic M, Glorieux FH, Cole WG, Mäkitie O (2003) Genetic changes in the RNA components of RNase MRP and RNase P in Schmid metaphyseal chondrodysplasia. *J Med Genet.* 2003 Oct;40(10):741-6 ([PMID: 14569119](#))
40. Ridanpää M, van Eenennaam H, Pelin K, Chadwick R, Johnson C, Yuan B, vanVenrooij W, Pruijn G, Salmela R, Rockas S, Mäkitie O, Kaitila I, de la Chapelle A (2001) Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia. *Cell.* 2001 Jan 26;104(2):195-203 ([PMID: 11207361](#))
41. Robertson N, Shchepachev V, Wright D, Turowski TW, Spanos C, Helwak A, Zamoyska R, Tollervey D (2022) A disease-linked lncRNA mutation in RNase MRP inhibits ribosome synthesis. *Nat Commun.* 2022 Feb 03;13(1):649. Epub 2022 Feb 3 ([PMID: 35115551](#))

42. Rogler LE, Kosmyrna B, Moskowitz D, Bebawee R, Rahimzadeh J, Kutchko K, Laederach A, Notarangelo LD, Giliani S, Bouhassira E, Frenette P, Roy-Chowdhury J, Rogler CE (2013) Small RNAs derived from lncRNA RNase MRP have gene-silencing activity relevant to human cartilage-hair hypoplasia. *Hum Mol Genet.* 2014 Jan 15;23(2):368-82. Epub 2013 Sep 5 ([PMID: 24009312](#))
43. Roifman CM, Gu Y, Cohen A (2006) Mutations in the RNA component of RNase mitochondrial RNA processing might cause Omenn syndrome. *J Allergy Clin Immunol.* 2006 Apr;117(4):897-903 ([PMID: 16630949](#))
44. Scocchia A, Kangas-Kontio T, Irving M, Hero M, Saarinen I, Pelttari L, Gall K, Valo S, Huusko JM, Tallila J, Sistonen J, Koskenvuo J, Alastalo TP (2021) Diagnostic utility of next-generation sequencing-based panel testing in 543 patients with suspected skeletal dysplasia. *Orphanet J Rare Dis.* 2021 Oct 09;16(1):412. Epub 2021 Oct 9 ([PMID: 34627339](#))
45. Scott EM, Chandra S, Li J, Robinette ED, Brown MF, Wenger OK (2020) Abnormal Newborn Screening Follow-up for Severe Combined Immunodeficiency in an Amish Cohort with Cartilage-Hair Hypoplasia. *J Clin Immunol.* 2020 Feb;40(2):321-328. Epub 2020 Jan 6 ([PMID: 31903518](#))
46. Sipilä K, Aula P (2002) Database for the mutations of the Finnish disease heritage. *Hum Mutat.* 2002 Jan;19(1):16-22 ([PMID: 11754099](#))
47. Sparber P, Filatova A, Khanemirova M, Skoblov M (2019) The role of long non-coding RNAs in the pathogenesis of hereditary diseases. *BMC Med Genomics.* 2019 Mar 13;12(Suppl 2):42 ([PMID: 30871545](#))
48. Steinbusch MMF, Caron MMJ, Surtel DAM, Friedrich F, Lausch E, Pruijn GJM, Verhesen W, Schroen BLM, van Rhijn LW, Zabel B, Welting TJM (2017) Expression of RMRP RNA is regulated in chondrocyte hypertrophy and determines chondrogenic differentiation. *Sci Rep.* 2017 Jul 25;7(1):6440 ([PMID: 28743979](#))
49. Steinbusch MMF, Caron MMJ, Surtel DAM, van den Akker GGH, van Dijk PJ, Friedrich F, Zabel B, van Rhijn LW, Peffers MJ, Welting TJM (2019) The antiviral protein viperin regulates chondrogenic differentiation via CXCL10 protein secretion. *J Biol Chem.* 2019 Mar 29;294(13):5121-5136. Epub 2019 Feb 4 ([PMID: 30718282](#))
50. Strand J, Gul KA, Erichsen HC, Lundman E, Berge MC, Tr  mborg AK, S  rgjerd LK, Ytre-Arne M, Hogner S, Halsne R, Gaup HJ, Osnes LT, Kro GAB, Sorte HS, M  rkrid L, Rowe AD, Tangeraas T, J  rgensen JV, Alme C, Bj  rndal  n TEH, R  nnestad AE, Lang AM, Rootwelt T, Buechner J,   verland T, Abrahamsen TG, Pettersen RD, Stray-Pedersen A (2020) Second-Tier Next Generation Sequencing Integrated in Nationwide Newborn Screening Provides Rapid Molecular Diagnostics of Severe Combined Immunodeficiency. *Front Immunol.* 2020;11:1417. Epub 2020 Jul 9 ([PMID: 32754152](#))
51. Stranneheim H, Lagerstedt-Robinson K, Magnusson M, Kvarnung M, Nilsson D, Lesko N, Engvall M, Anderlid BM, Arnell H, Johansson CB, Barbaro M, Bj  rck E, Bruhn H, Einfeldt J, Freyer C, Grigelioniene G, Gustavsson P, Hammarsj   A, Hellstr  m-Pigg M, Iwarsson E, Jemt A, Laaksonen M, Enoksson SL, Malmgren H, Naess K, Nordenskj  ld M, Oscarson M, Pettersson M, Rasi C, Rosenbaum A, Sahlin E, Sardh E, St  lberg T, Tesi B, Tham E, Thonberg H, T  h  nen V, von D  beln U, Vassiliou D, Vonlanthen S, Wikstr  m AC, Wincent J, Winqvist O, Wredenberg A, Ygberg S, Zetterstr  m RH, Marits P, Solter MJ, Nordgren A, Wirta V, Lindstrand A, Wedell A (2021) Integration of whole genome sequencing into a healthcare setting: high diagnostic rates across multiple clinical entities in 3219 rare disease patients. *Genome Med.* 2021 Mar 17;13(1):40 ([PMID: 33726816](#))
52. Strauss KA, Puffenberger EG (2009) Genetics, medicine, and the Plain people. *Annu Rev Genomics Hum Genet.* 2009;10:513-36 ([PMID: 19630565](#))
53. Tanner AK, Valencia CA, Rhodenizer D, Espirages M, Da Silva C, Borsuk L, Caldwell S, Gregg E, Grimes E, Lichanska AM, Morris L, Purkayastha A, Weslowski B, Tibbetts C, Lorence MC, Hegde M (2014) Development and performance of a comprehensive targeted sequencing assay for pan-ethnic screening of carrier status. *J Mol Diagn.* 2014 May;16(3):350-60. Epub 2014 Feb 8 ([PMID: 24517888](#))
54. Taskinen M, Ranki A, Pukkala E, Jeskanen L, Kaitila I, M   kitie O (2008) Extended follow-up of the Finnish cartilage-hair hypoplasia cohort confirms high incidence of non-Hodgkin lymphoma and basal cell carcinoma. *Am J Med Genet A.* 2008 Sep 15;146A(18):2370-5 ([PMID: 18698627](#))
55. Thiel CT, Horn D, Zabel B, Ekici AB, Salinas K, Gebhart E, R  tschendorf F, Sticht H, Spranger J, M  ller D, Zweier C, Schmitt ME, Reis A, Rauch A (2005) Severely incapacitating mutations in patients with extreme short stature identify RNA-processing endoribonuclease RMRP as an essential cell growth regulator. *Am J Hum Genet.* 2005 Nov;77(5):795-806. Epub 2005 Sep 29 ([PMID: 16252239](#))

56. Thiel CT, Mortier G, Kaitila I, Reis A, Rauch A (2007) Type and level of RMRP functional impairment predicts phenotype in the cartilage hair hypoplasia-anauxetic dysplasia spectrum. *Am J Hum Genet.* 2007 Sep;81(3):519-29. Epub 2007 Aug 6 ([PMID: 17701897](#))
57. Thiel CT, Rauch A (2011) The molecular basis of the cartilage-hair hypoplasia-anauxetic dysplasia spectrum. *Best Pract Res Clin Endocrinol Metab.* 2011 Feb;25(1):131-42 ([PMID: 21396580](#))
58. Vakkilainen S, Costantini A, Taskinen M, Wartiovaara-Kautto U, Mäkitie O (2019) 'Metaphyseal dysplasia without hypotrichosis' can present with late-onset extraskeletal manifestations. *J Med Genet.* 2020 Jan;57(1):18-22. Epub 2019 Aug 14 ([PMID: 31413121](#))
59. Vakkilainen S, Skoog T, Einarsdottir E, Middleton A, Pekkinen M, Åhman T, Katayama S, Krjut'kov K, Kovanen PE, Varjosalo M, Lindqvist A, Kere J, Mäkitie O (2019) The human long non-coding RNA gene RMRP has pleiotropic effects and regulates cell-cycle progression at G2. *Sci Rep.* 2019 Sep 24;9(1):13758 ([PMID: 31551465](#))
60. Venturi G, Montanaro L (2020) How Altered Ribosome Production Can Cause or Contribute to Human Disease: The Spectrum of Ribosomopathies. *Cells.* 2020 Oct 15;9(10) ([PMID: 33076379](#))
61. Wallander K, Thonberg H, Nilsson D, Tham E (2021) Massive parallel sequencing in individuals with multiple primary tumours reveals the benefit of re-analysis. *Hered Cancer Clin Pract.* 2021 Oct 28;19(1):46 ([PMID: 34711244](#))
62. Welting TJ, van Venrooij WJ, Pruijn GJ (2004) Mutual interactions between subunits of the human RNase MRP ribonucleoprotein complex. *Nucleic Acids Res.* 2004;32(7):2138-46. Epub 2004 Apr 19 ([PMID: 15096576](#))
63. Williams MS, Ettinger RS, Hermanns P, Lee B, Carlsson G, Taskinen M, Mäkitie O (2005) The natural history of severe anemia in cartilage-hair hypoplasia. *Am J Med Genet A.* 2005 Sep 15;138(1):35-40 ([PMID: 16097009](#))
64. Zährnäck 1/2 T, Heikkinen A, Kangas SM, Karikoski M, Martínez-Nieto GA, Salo MH, Uusimaa J, Vuolteenaho R, Hinttala R, Sipilä P, Kuure S (2021) Modeling Rare Human Disorders in Mice: The Finnish Disease Heritage. *Cells.* 2021 Nov 13;10(11) ([PMID: 34831381](#))
65. de la Fuente MA, Recher M, Rider NL, Strauss KA, Morton DH, Adair M, Bonilla FA, Ochs HD, Gelfand EW, Pessach IM, Walter JE, King A, Giliani S, Pai SY, Notarangelo LD (2011) Reduced thymic output, cell cycle abnormalities, and increased apoptosis of T lymphocytes in patients with cartilage-hair hypoplasia. *J Allergy Clin Immunol.* 2011 Jul;128(1):139-146. Epub 2011 May 13 ([PMID: 21570718](#))
66. Äzbek N (2009) New insights into the genetics of congenital neutropenia. *Turk J Haematol.* 2009 Mar 05;26(1):1-8 ([PMID: 27265100](#))
67. ClinVar: RCV000313899.2
68. OMIM gene/allele: 157660.0001
69. HGMD mutation: CR011576
70. OMIM phenotype: 250460
71. ClinVar: RCV000763613.1
72. ClinVar: RCV000015275.31
73. OMIM phenotype: 250250
74. ClinVar: RCV000015276.31
75. ClinVar: RCV000555900.6